Insulet Initiates Voluntary Correction for Omnipod Pods After Cannula Tear Defect Identified

A cannula integrity failure affecting approximately 7 million Omnipod pods has prompted Insulet Corporation to issue a voluntary Medical Device Correction spanning Omnipod 5, Omnipod DASH, and Omnipod Eros lots distributed in the U.S. and select international markets, the company's second such action in under three months. For QA directors and manufacturing leads, the sequence of events is instructive: the defect was detected through ongoing product monitoring, not a field complaint surge, and corrective actions were implemented before the public notification.

The identified defect involves a small tear in the cannula tubing just above the skin, between the pod body and the subcutaneous insertion point. Insulin leakage at this junction can result in under-delivery, with downstream clinical consequences ranging from elevated blood glucose to diabetic ketoacidosis. Globally, 24 serious adverse events, including hospitalizations and DKA cases, have been attributed to the issue; no fatalities have been reported. Insulet notes that approximately 60% of affected lots have already been consumed or expired, and the in-scope pods represent roughly 8.5% of 2025 global Omnipod production.

The CAPA read here is direct. Insulet states it has identified root cause, implemented corrective actions to prevent recurrence, and strengthened in-process monitoring controls specifically designed to detect cannula tears of this nature. That sequence, surveillance detection, root cause analysis, in-process control enhancement, maps to the ICH Q10 pharmaceutical quality system model and reflects the kind of proactive CAPA architecture that regulators expect to see documented under 21 CFR Part 820 for device manufacturers. The prior March 12, 2026 correction, which covered certain Omnipod 5 pods separately, suggests the monitoring infrastructure was already generating signals; the question for internal quality teams reviewing analogous programs is whether their own surveillance cadence would surface a defect at this detection threshold.

The FDA and all relevant international regulatory authorities have been notified. Insulet has confirmed sufficient replacement supply is available and does not anticipate product availability disruption, a supply-chain posture that limits patient impact but does not reduce the compliance documentation burden associated with a correction of this scale.

Lot-specific verification and replacement pod requests remain available through Insulet's dedicated portal, with 24/7 product support accessible in the U.S. at 1-800-641-2049; the measurable outcome to track is the rate at which affected, unconsumed pods are identified and replaced before further adverse events are recorded.

Source: FDA MedWatch Safety Alerts via fda.gov, May 26, 2026.